CN1076020C - 来苏必通二盐酸盐的新晶型和其水合物、制备方法和组合物 - Google Patents

来苏必通二盐酸盐的新晶型和其水合物、制备方法和组合物 Download PDF

Info

Publication number
CN1076020C
CN1076020C CN96190703A CN96190703A CN1076020C CN 1076020 C CN1076020 C CN 1076020C CN 96190703 A CN96190703 A CN 96190703A CN 96190703 A CN96190703 A CN 96190703A CN 1076020 C CN1076020 C CN 1076020C
Authority
CN
China
Prior art keywords
lysol
lead
dihydrochloride
hydrate
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96190703A
Other languages
English (en)
Chinese (zh)
Other versions
CN1158128A (zh
Inventor
P·卢庞·罗塞斯
J·托马斯·纳瓦洛
S·普杰·托利斯
J·弗里格拉·康斯坦萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CN1158128A publication Critical patent/CN1158128A/zh
Application granted granted Critical
Publication of CN1076020C publication Critical patent/CN1076020C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN96190703A 1995-05-31 1996-05-29 来苏必通二盐酸盐的新晶型和其水合物、制备方法和组合物 Expired - Fee Related CN1076020C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES09501086A ES2099031B1 (es) 1995-05-31 1995-05-31 Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
ESP9501086 1995-05-31

Publications (2)

Publication Number Publication Date
CN1158128A CN1158128A (zh) 1997-08-27
CN1076020C true CN1076020C (zh) 2001-12-12

Family

ID=8290585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96190703A Expired - Fee Related CN1076020C (zh) 1995-05-31 1996-05-29 来苏必通二盐酸盐的新晶型和其水合物、制备方法和组合物

Country Status (29)

Country Link
US (1) US5872125A (enExample)
EP (1) EP0771798A1 (enExample)
JP (1) JPH10503532A (enExample)
CN (1) CN1076020C (enExample)
AR (1) AR003952A1 (enExample)
AU (1) AU699210B2 (enExample)
BG (1) BG62966B1 (enExample)
CA (1) CA2196425A1 (enExample)
CO (1) CO4700461A1 (enExample)
CZ (1) CZ24797A3 (enExample)
EE (1) EE9700067A (enExample)
ES (1) ES2099031B1 (enExample)
GE (1) GEP20002241B (enExample)
HU (1) HUP9700284A3 (enExample)
IL (1) IL118494A0 (enExample)
IN (1) IN186820B (enExample)
IS (1) IS4420A (enExample)
MA (1) MA23883A1 (enExample)
MX (1) MX9700792A (enExample)
NO (1) NO310073B1 (enExample)
NZ (1) NZ308110A (enExample)
PL (1) PL318280A1 (enExample)
RU (1) RU2178789C2 (enExample)
SK (1) SK12697A3 (enExample)
TR (1) TR199600455A2 (enExample)
UY (1) UY24241A1 (enExample)
WO (1) WO1996038439A1 (enExample)
YU (1) YU32396A (enExample)
ZA (1) ZA964139B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497658A1 (fr) * 1991-01-25 1992-08-05 Laboratorios Del Dr. Esteve, S.A. Utilisation de dérivés 1-H-azole-(omega-(4-(2-pyrimidinyl)-1-pipérazinyl)-alkyl) pour la préparation de médicaments destinés au traitement des troubles des fonctions cognitives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994455A (en) * 1987-10-26 1991-02-19 Pfizer Inc. Anti-anxiety agents
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2654621B1 (fr) * 1989-11-22 1994-09-23 Esteve Labor Dr Inhibition du syndrome d'abstinence.
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
JP3001281B2 (ja) * 1991-03-06 2000-01-24 日本碍子株式会社 ハニカムモノリスヒータ
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497658A1 (fr) * 1991-01-25 1992-08-05 Laboratorios Del Dr. Esteve, S.A. Utilisation de dérivés 1-H-azole-(omega-(4-(2-pyrimidinyl)-1-pipérazinyl)-alkyl) pour la préparation de médicaments destinés au traitement des troubles des fonctions cognitives

Also Published As

Publication number Publication date
US5872125A (en) 1999-02-16
HU9700284D0 (en) 1997-04-28
AU5765096A (en) 1996-12-18
JPH10503532A (ja) 1998-03-31
YU32396A (sh) 1999-07-28
PL318280A1 (en) 1997-06-09
MX9700792A (es) 1997-05-31
HUP9700284A3 (en) 1998-01-28
ES2099031A1 (es) 1997-05-01
GEP20002241B (en) 2000-09-25
CO4700461A1 (es) 1998-12-29
IS4420A (is) 1997-01-29
NZ308110A (en) 1997-08-22
CZ24797A3 (en) 1997-05-14
CN1158128A (zh) 1997-08-27
ES2099031B1 (es) 1997-12-01
RU2178789C2 (ru) 2002-01-27
NO970392D0 (no) 1997-01-29
NO310073B1 (no) 2001-05-14
TR199600455A2 (tr) 1996-12-21
EE9700067A (et) 1997-10-15
SK12697A3 (en) 1997-07-09
EP0771798A1 (en) 1997-05-07
BG62966B1 (bg) 2000-12-29
MA23883A1 (fr) 1996-12-31
IL118494A0 (en) 1996-09-12
BG101176A (en) 1997-08-29
IN186820B (enExample) 2001-11-17
AR003952A1 (es) 1998-09-30
WO1996038439A1 (es) 1996-12-05
ZA964139B (en) 1997-02-06
AU699210B2 (en) 1998-11-26
HUP9700284A2 (en) 1997-11-28
CA2196425A1 (en) 1996-12-05
NO970392L (no) 1997-04-01
UY24241A1 (es) 1996-06-14

Similar Documents

Publication Publication Date Title
KR102006200B1 (ko) 매크로라이드의 결정 형태들 및 그 용도들
JP7241916B2 (ja) ７ｈ－ピロロ［２，３－ｄ］ピリミジンｊａｋ－阻害剤
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
CN1373126A (zh) 结晶形式的n－(4－三氟甲基苯基)－5－甲基异噁唑－4－甲酰胺
US7759481B2 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
US11897858B2 (en) Salt and solid state forms of escatalopram
CN102174027B (zh) 利奈唑胺的新晶型及其制备方法和用途
CN1735620A (zh) 纯的左氧氟沙星半水合物和它的制备方法
CN1076020C (zh) 来苏必通二盐酸盐的新晶型和其水合物、制备方法和组合物
CN107793368A (zh) 达可替尼溶剂化物、其新晶型及其制备方法和用途
WO2014036865A1 (zh) 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN102256951B (zh) 结晶水合物、药物组合物及其用途
CN1291978C (zh) 5－羟基－1－甲基乙内酰脲的新型晶型
CN119630666A (zh) 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用
CN105992769A (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
WO2021119223A1 (en) Solid state form of lemborexant
SK143697A3 (en) A process for preparing form 1 ranitidine hydrochloride
CN1789273A (zh) 一种阿奇霉素的可溶性盐及其制备方法
CN1257478A (zh) 用作抗－心律不齐药物的硝基苯甲酰胺
EP4229057A1 (en) Solid state forms of lorecivivint
WO2025032195A1 (en) Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate
CN121085927A (zh) 一种巴瑞克替尼草酸盐结晶形式及其制备方法
HK1227882A1 (en) L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound
HK1017681B (en) Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox
CN106543164A (zh) 稳定的苏沃雷生化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee